Experts are now urging the FDA to ban the use of phenylpropanolamine (PPA) in OTC products.
Experts are now urging the FDA to ban the use of phenylpropanolamine (PPA) in OTC products.
This is due to a possible increased risk of hemorrhagic stroke...especially in young women using appetite suppressants and patients taking OTC cough and cold products that contain PPA.
For now, warn patients not to exceed recommended doses of PPA-containing products...Contac, Dimetapp, Triaminic, etc.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote